Merging of the Fukushima Health Management Survey With the National and Local Cancer Registry to Refine the Detection of Thyroid Cancer Cases After the 2011 Fukushima Daiichi Nuclear Power Plant Accident

IF 3.1 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-02-06 DOI:10.1002/cam4.70610

Reiko Kimura-Tsuchiya, Masanori Nagao, Shigehira Saji, Fumikazu Hayashi, Tetsuya Ohira, Hiroki Shimura, Fumihiko Furuya, Satoru Suzuki, Satoshi Suzuki, Tetsuo Ishikawa, Susumu Yokoya, Hitoshi Ohto, Seiji Yasumura

{"title":"Merging of the Fukushima Health Management Survey With the National and Local Cancer Registry to Refine the Detection of Thyroid Cancer Cases After the 2011 Fukushima Daiichi Nuclear Power Plant Accident","authors":"Reiko Kimura-Tsuchiya, Masanori Nagao, Shigehira Saji, Fumikazu Hayashi, Tetsuya Ohira, Hiroki Shimura, Fumihiko Furuya, Satoru Suzuki, Satoshi Suzuki, Tetsuo Ishikawa, Susumu Yokoya, Hitoshi Ohto, Seiji Yasumura","doi":"10.1002/cam4.70610","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>After the Fukushima Daiichi Nuclear Power Plant accident in 2011, the Fukushima Health Management Survey (FHMS) was implemented in Fukushima Prefecture to promote long-term health care. The FHMS included thyroid ultrasound examination (TUE) for individuals aged ≤ 18 years, including fetuses at the time of the accident. However, the FHMS may not have captured all cases of thyroid cancer because it only followed up with examinees. To address this gap, we aimed to merge individual-level information from the FHMS with national and local cancer registries (CRs) to determine the limitations of the FHMS and CRs in capturing thyroid cancer cases.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The FHMS-eligible residents' information was supplemented by merging and cross-validating the FHMS and CR data using the Fukushima Prefectural Cancer Registry (FPCR), 2008–2015, and the National Cancer Registry (NCR), 2016–2018. For analysis, registered cases were classified into three groups: registered in both the CR and FHMS, or only in the CRs, or only in the FHMS. The characteristics of each case were evaluated in each database.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In the FHMS, 212 thyroid cancer cases were identified through 2018, with another 42 cases identified in the CRs. Of the 176 thyroid cancer cases registered until 2015, 28 (15.9%) were identified in the FHMS only and 13 (7.4%) in the FPCR only. Of the 78 additional cases identified since 2016, 29 (37.2%) were identified in the NCR only and 6 (7.7%) in the FHMS only. This indicates that the NCR captured the cases more efficiently than the FPCR.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Merging data from the FHMS and CRs at the individual level is necessary to capture thyroid cancer cases more accurately after the 2011 nuclear accident.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 3","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70610","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70610","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

After the Fukushima Daiichi Nuclear Power Plant accident in 2011, the Fukushima Health Management Survey (FHMS) was implemented in Fukushima Prefecture to promote long-term health care. The FHMS included thyroid ultrasound examination (TUE) for individuals aged ≤ 18 years, including fetuses at the time of the accident. However, the FHMS may not have captured all cases of thyroid cancer because it only followed up with examinees. To address this gap, we aimed to merge individual-level information from the FHMS with national and local cancer registries (CRs) to determine the limitations of the FHMS and CRs in capturing thyroid cancer cases.

Methods

The FHMS-eligible residents' information was supplemented by merging and cross-validating the FHMS and CR data using the Fukushima Prefectural Cancer Registry (FPCR), 2008–2015, and the National Cancer Registry (NCR), 2016–2018. For analysis, registered cases were classified into three groups: registered in both the CR and FHMS, or only in the CRs, or only in the FHMS. The characteristics of each case were evaluated in each database.

Results

In the FHMS, 212 thyroid cancer cases were identified through 2018, with another 42 cases identified in the CRs. Of the 176 thyroid cancer cases registered until 2015, 28 (15.9%) were identified in the FHMS only and 13 (7.4%) in the FPCR only. Of the 78 additional cases identified since 2016, 29 (37.2%) were identified in the NCR only and 6 (7.7%) in the FHMS only. This indicates that the NCR captured the cases more efficiently than the FPCR.

Conclusion

Merging data from the FHMS and CRs at the individual level is necessary to capture thyroid cancer cases more accurately after the 2011 nuclear accident.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2011年福岛第一核电站事故后，将福岛健康管理调查与国家和地方癌症登记处合并以改进甲状腺癌病例的检测

2011年福岛第一核电站事故发生后，福岛县实施了福岛健康管理调查（FHMS），以促进长期卫生保健。FHMS包括年龄≤18岁的个体（包括事故发生时的胎儿）的甲状腺超声检查（TUE）。然而，FHMS可能没有捕捉到所有的甲状腺癌病例，因为它只是对考生进行了随访。为了解决这一差距，我们的目标是将FHMS的个人水平信息与国家和地方癌症登记处（CRs）合并，以确定FHMS和CRs在捕获甲状腺癌病例方面的局限性。方法利用福岛县2008-2015年癌症登记（FPCR）和2016-2018年国家癌症登记（NCR），合并并交叉验证FHMS和CR数据，补充符合FHMS条件的居民信息。为便于分析，将登记病例分为三组：在户籍登记和家庭卫生管理系统中均登记，或仅在户籍登记系统中登记，或仅在家庭卫生管理系统中登记。在每个数据库中评估每个病例的特征。结果在FHMS中，到2018年发现了212例甲状腺癌病例，在CRs中发现了另外42例。截至2015年登记的176例甲状腺癌病例中，28例（15.9%）仅在FHMS中被发现，13例（7.4%）仅在FPCR中被发现。在自2016年以来发现的78例新增病例中，29例（37.2%）仅在NCR中发现，6例（7.7%）仅在FHMS中发现。这表明NCR比FPCR更有效地捕获病例。结论2011年核事故后，为了更准确地捕获甲状腺癌病例，有必要将FHMS和CRs数据在个体水平上合并。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.